Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12065768rdf:typepubmed:Citationlld:pubmed
pubmed-article:12065768lifeskim:mentionsumls-concept:C0282552lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0333348lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0312861lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C1710548lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C0971580lld:lifeskim
pubmed-article:12065768lifeskim:mentionsumls-concept:C1363844lld:lifeskim
pubmed-article:12065768pubmed:issue1lld:pubmed
pubmed-article:12065768pubmed:dateCreated2002-6-14lld:pubmed
pubmed-article:12065768pubmed:abstractTextThe recently discovered CC chemokine, regakine-1, is constitutively present in bovine serum and synergizes with the CXC chemokine interleukin-8 (IL-8) to chemoattract neutrophils. Here we show that regakine-1 cooperates with the CXC chemokine receptor 2 ligand neutrophil activating protein-2 (NAP-2) and the anaphylatoxin C5a, two other mediators of inflammation present in the circulation. Neutrophil chemotaxis was 3-fold enhanced when regakine-1 (100 ng/ml) and C5a (30 ng/ml) were combined at concentrations present in bovine or human plasma, respectively. This synergy was also observed when neutrophils were preincubated with regakine-1. Plasma chemokines such as NAP-2, beta-thromboglobulin, and hemofiltrate CC-chemokine-1 did not affect C5a chemotactic activity. The capability of regakine-1 to synergize with C5a, NAP-2, or N-formyl-methionyl-leucyl-phenylalanine (fMLP) was not observed for monocyte chemotactic protein-3 (MCP-3), another CC chemokine that weakly chemoattracts neutrophils. Regakine-1 also failed to cooperate with MCP-3 and macrophage inflammatory protein-1alpha in neutrophil chemotaxis. The receptor of regakine-1 is not known yet. Competition with labeled fMLP or C5a for binding to neutrophils or receptor transfected cell lines demonstrated that regakine-1 did not alter receptor recognition. The protein kinase inhibitors 2'-amino-3'-methoxyflavone (PD98059), wortmannin and staurosporin had no effect on the synergy between C5a and regakine-1. Although NH2-terminal truncation affects the chemotactic potency of most chemokines, it did not affect the synergistic capacity of regakine-1 with C5a on neutrophils. These findings indicate that the constitutive plasma chemokine regakine-1 is a stable enhancer of the inflammatory response and that its blockade might be beneficial in acute and systemic inflammatory disorders.lld:pubmed
pubmed-article:12065768pubmed:languageenglld:pubmed
pubmed-article:12065768pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:citationSubsetIMlld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12065768pubmed:statusMEDLINElld:pubmed
pubmed-article:12065768pubmed:monthJullld:pubmed
pubmed-article:12065768pubmed:issn0026-895Xlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:ProostPaulPlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:Van DammeJoJlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:StruyfSofieSlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:GouwyMiekeMlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:MahieuFrankFlld:pubmed
pubmed-article:12065768pubmed:authorpubmed-author:PutWillyWlld:pubmed
pubmed-article:12065768pubmed:issnTypePrintlld:pubmed
pubmed-article:12065768pubmed:volume62lld:pubmed
pubmed-article:12065768pubmed:ownerNLMlld:pubmed
pubmed-article:12065768pubmed:authorsCompleteYlld:pubmed
pubmed-article:12065768pubmed:pagination173-80lld:pubmed
pubmed-article:12065768pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:meshHeadingpubmed-meshheading:12065768...lld:pubmed
pubmed-article:12065768pubmed:year2002lld:pubmed
pubmed-article:12065768pubmed:articleTitleThe unique property of the CC chemokine regakine-1 to synergize with other plasma-derived inflammatory mediators in neutrophil chemotaxis does not reside in its NH2-terminal structure.lld:pubmed
pubmed-article:12065768pubmed:affiliationLaboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.lld:pubmed
pubmed-article:12065768pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12065768pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:12065768pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12065768lld:pubmed